Integration of novel agents into first-line therapy for newly diagnosed multiple myeloma (MM) patients who are eligible to receive an autologous stem cell transplantation (ASCT) has led to unprecedented rates of high-quality responses.1 Based on the results of several phase III trials,2, 3, 4, 5 a three-drug induction regimen including bortezomib and dexamethasone (VD) is currently considered the standard of care in preparation for ASCT. The European Medicines Agency recently approved the combination of bortezomib with thalidomide and dexamethasone (VTD) for this use.
Cavo, M., Pantani, L., Pezzi, A., Petrucci, M.T., Patriarca, F., Di Raimondo, F., et al. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. LEUKEMIA, 29(12), 2429-2431 [10.1038/leu.2015.274].
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
CAVO, MICHELE;PANTANI, LUCIA;PEZZI, ANNALISA;MARZOCCHI, GIULIA;ZAMAGNI, ELENA;GAMBERI, BARBARA;TACCHETTI, PAOLA;BRIOLI, ANNAMARIA;
2015
Abstract
Integration of novel agents into first-line therapy for newly diagnosed multiple myeloma (MM) patients who are eligible to receive an autologous stem cell transplantation (ASCT) has led to unprecedented rates of high-quality responses.1 Based on the results of several phase III trials,2, 3, 4, 5 a three-drug induction regimen including bortezomib and dexamethasone (VD) is currently considered the standard of care in preparation for ASCT. The European Medicines Agency recently approved the combination of bortezomib with thalidomide and dexamethasone (VTD) for this use.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
